1. The overdose of drugs in Japan Nature
    Fukushima M. Nature. 1989;342(6252):850-851. doi:10.1038/342850a0
  2. Clinical trials in Japan
    Fukushima M. Nat Med 1, 12–13 (1995). https://doi.org/10.1038/nm0195-12
  3. Projection of creutzfeldt-jakob disease frequency based on cadaveric dura transplantation in Japan
    Hamada C, Sadaike T, Fukushima M. Neuroepidemiology. 2003;22(1):57-64. doi:10.1159/000067103
  4. Creutzfeldt-Jakob Disease and Cadaveric Dura Mater Grafts in Japan: An Updated Analysis of Incubation Time
    Shigeyuki Matsui, Tetsuji Sadaike, Chikuma Hamada, Masanori Fukushima; Neuroepidemiology
    1 December 2004; 24 (1-2): 22–25. https://doi.org/10.1159/000081045
  5. Size of Creutzfeldt-Jakob disease epidemic associated with cadaveric dura transplantation
    Tanaka S, Fukushima M. Neuroepidemiology. 2010;34(4):232-237. doi:10.1159/00029774
  6. Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures
    Nishimura T, Tada H, Nakagawa M, Teramukai S, Matsui S, Fukushima M. Pharm Pract (Granada). 2006;4(4):168-178.
    doi:10.4321/s1885-642×2006000400004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155619/
  7. Lessons from Gefitinib-induced Interstitial Lung Disease: Pharmacovigilance for Erlotinib in Japan
    Nishimura, Tsutomu, Tada, Harue, and Fukushima, Masanori. 1 Jan. 2009 : 161 – 167.